Emerging at the UK, retatrutide, a new molecule, is sparking considerable interest within the scientific community regarding its potential for body regulation. This dual GIP and GLP-1 agent agonist looks to provide a significant benefit over current therapies, showing encouraging results in initial clinical assessments. Researchers believe its part